Home

 

LEADING ALZHEIMER'S RESEARCHER TALKS ABOUT LITHIUM ALTERNATIVE

AULT LIFE SCIENCES WORKING WITH UNIVERSITIES

Ault Life Sciences

OUR APPROACH

Ault Life Sciences invests in disruptive technologies and processes in the biotechnology and health care sectors. Although our structure may be corporate, our approach with our stakeholders is one of partnership. Our proactive value-added investment approach combined with our team’s diligence and expertise has us strategically positioned for explosive growth in the near future.

Ault Life Sciences

OUR MISSION

Disciplined focus on neuro-degenerative diseases and the biotechnology sector where Ault Life Sciences expertise can drive exponential growth.

In my 30 years on Wall Street, I have come to understand the risks and rewards associated with investing in innovative life science companies. Having benefited from numerous successful transactions in this sector, I have now created a new venture, Ault Life Sciences. This was done to both support a promising new company (Alzamend Neuro) in advancing two treatments for Alzheimer’s disease and to uncover additional promising companies and technologies with a focus on treating neuro-degenerative diseases. Our leadership team and network of scientific experts are in position as we look to capture the tremendous upside potential of the life sciences sector.
Todd Ault, Founder of Ault Life Sciences
Portfolio

Investment Portfolio

ALZAMEND NEURO
News & Press

Alzamend News

Alzamend Neuro™ Announces Appointment of Dr. Eric McDade to Its Scientific Advisory Board

July 16th, 2019
Ault Life Sciences, Inc.

Alzamend Neuro™ Announces Senior Management to Participate in the 2019 Alzheimer’s Association International Conference®

July 12th, 2019
Ault Life Sciences, Inc.

Alzamend Neuro™ Announces First Appointment to Scientific Advisory Board

July 9th, 2019
Ault Life Sciences, Inc.

Alzamend Neuro™ Completes New Management Team for 2019

December 26th, 2018
Ault Life Sciences, Inc.

Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman

November 20th, 2018
Ault Life Sciences, Inc.

Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease

October 29th, 2018
Ault Life Sciences, Inc.
Scroll to top